AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02586363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude Tab. 0.5mg, fasting
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: d1 5-FU 250 mg/m² every two weeks
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: d1 Leucovorin 400 mg every two weeks
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: d1 Leucovorin 400 mg every two weeks
Study NCT05234996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3 Virtual Reality headset (VR Headset),
Description: The VRE will administer through the use of 3 Virtual Reality headset (VR Headset), containing a selection of audiovisual productions made with 360 degrees technology and selected on the basis of content, plot and production dynamics.
Study NCT01170143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab QW, Trastuzumab Q3W
Description: two arms using Trastuzumab QW vs Q3W
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: d1 5-FU 400 mg/m² every two weeks
Study NCT04442984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: d1-2 5-FU 2400 mg/m² every two weeks
Study NCT03521323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
Study NCT03521323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos: Saline，Sham operation
Study NCT04655118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.
Study NCT04655118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match TL-895
Study NCT02510235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin
Description: Lubricin 150 µg/ml eye drops
Study NCT02510235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium hyaluronate 0.13% eye drops
Study NCT01448291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Description: Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
Study NCT01180413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
Study NCT01180413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
Study NCT01180413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Description: Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
Study NCT02586363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavir Tab. 0.5mg, fasting
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study NCT02586363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavir Tab. 0.5mg, high fatty meal
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study NCT01180413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
Study NCT02241395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrathecal autologous bone marrow mononuclear cell transplantation
Study NCT04190784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
Study NCT02775578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting
Description: Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
Study NCT02775578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
Study NCT02775578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Coronary Revascularization
Description: Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
Study NCT04190784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo stretching
Description: The therapist maintains the same manual contact without stretching force.
Study NCT01229488 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Intervention
Description: Project was withdrawn before starting. There were no interventions
Study NCT04152525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
Study NCT03707652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement A
Description: 1, 2 or 4 capsules daily of oral supplement A for 3 days
Study NCT03707652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement B
Description: 4 capsules daily of oral supplement B for 3 days
Study NCT01102270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: 3mg tablet once prior to sleep
Study NCT03707652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement C
Description: 1,2 or 4 capsules daily of oral supplement C for 3 days
Study NCT03707652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement D
Description: 1 or 2 tablets daily of oral supplement D for 3 days
Study NCT00508040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alpha 2a
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
Study NCT00508040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon alpha 2a
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
Study NCT00508040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
Study NCT00508040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
Study NCT00697840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 2 doses
Study NCT00697840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL 208129
Description: Intramuscular injection, 2 doses
Study NCT00697840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation
Description: Intramuscular injection, 2 doses; experimental formulation
Study NCT04596397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient setting
Description: These women stay at the hospital.
Study NCT04596397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient setting
Description: These women can leave the hospital.
Study NCT03795389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM199
Description: Single SC dose
Study NCT02036801 — intervention group
Intervention type: OTHER
Intervention: Lung specific elastance
Description: Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
Study NCT03707652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Supplement D in combination with oral supplement C
Description: 1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
Study NCT01102270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule prior to sleep
Study NCT01720056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Study NCT00125658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
Study NCT00125658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
Study NCT03408353 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03408353 — intervention group
Intervention type: PROCEDURE
Intervention: Mammography
Description: Undergo standard of care mammography
Study NCT03408353 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT02551185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Study NCT01720056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog 10
Study NCT03086993 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS
Description: Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
Study NCT03086993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin and Gemcitabine
Description: continuous treatment with Cis/Gem until disease progression
Study NCT02283619 — intervention group
Intervention type: OTHER
Intervention: None - no intervention, observational study
Description: No intervention, observational study
Study NCT03663946 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT01633073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme: control device
Description: LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
Study NCT01633073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel: comparison device
Description: i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
Study NCT00900237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eslicarbazepine acetate
Description: Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
Study NCT00900237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
Study NCT02479607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone or tablet
Study NCT03016130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
Study NCT00887640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
Study NCT00887640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
Study NCT03861221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBBCT
Description: To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
Study NCT01553513 — intervention group
Intervention type: OTHER
Intervention: [18F]-FDG positron emission computed tomography
Description: Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest.
Study NCT03190720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile community
Description: A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
Study NCT01876238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PAT
Study NCT01876238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: Pre-test and posttest surveys and questionnaires
Study NCT01876238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Pre-test and posttest surveys and questionnaires
Study NCT02496637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite Awareness
Description: Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
Study NCT02496637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
Study NCT00488033 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Angiography
Description: If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
Study NCT01301742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 10773
Description: 1 tablet single dose BI 10773 in the morning
Study NCT01301742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemfibrozil
Description: Gemfibrozil 600 mg bid for 5 days
Study NCT01301742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: 1 tablet single dose BI 10773 in the morning
Study NCT00395252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux®) and Gemcitabine
Description: Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion
Study NCT00136747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Two capsules of Memantine twice daily for 12 days.
Study NCT00175097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet: soybeans and products made thereof
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
Study NCT00175097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet: soybean flour and products made thereof
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
Study NCT00175097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet: soybean milk
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
Study NCT00175097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet: Animal protein based diet
Description: The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
Study NCT03730779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Patients will receive nocturnal normobaric hyperoxia therapy
Study NCT02190279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F DCFBC
Description: Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
Study NCT02190279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
Study NCT03055741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5mg or 10mg, once a day, 24 weeks
Study NCT03055741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5mg or 10mg, once a day, 24 weeks
Study NCT03055741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP1401
Description: Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
Study NCT03055741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administrated in two divided dosed a day for 24 weeks
Study NCT01722955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-warmed fluids
Description: IV fluid will be stored at 41℃ set hot cabinet for 8hours
Study NCT01722955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room temperature fluids
Description: Room temperature fluid will be stored at ambient temperature
Study NCT00867048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All licensed antiretroviral medications
Description: In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
Study NCT00867048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All licensed antiretroviral medications
Description: In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
Study NCT02872350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound
Description: Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
Study NCT00810628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Individual interviews and group discussion/training.